I posted the below notes today to a small group of other investors with whom I interact (about 5-7 people). They already know about IPIX but many are in another play and only monitoring IPIX so I keep them informed with recent info on a regular basis. Just my WAG as to what is coming down the pike for IPIX. Most of them think they have a hot stock but it pales in comparison to IPIX potential IMO. I do believe that for many IPIX sounds just too good to be true. I'd feel the same if I hadn't been following it for years. My poor wife is finally going to see that my yearly "This is going to be a good XMAS" prediction for my stocks is finally going to come thru in spades this year.

Update on recent PR's - IPIX recently PR'd that they had completed enrollment for the Brilacidin-Oral Mucositis trial at 61 patients. Took them 2 years to get first 30 and 4 months for last 31, leading many to believe speed was caused by great results from earlier trial participants. Trial should now be over late Oct and results expected sometime around end of Nov. This definition (OM) already designated as fast track so many believe the additional sites set up recently are for the OM trial to go immediately into a Phase III. Hope they are right. IPIX also this week put up a new blog piece on OM and IMO they wouldn't have done it if the trial wasn't going extremely well. Thus, we now should have 4 trials that are going to be positive and the only remaining one is Kevetrin which should be done around the end of the year. I think the chances of IPIX running the table on 5 Phase II trials being successful this year is going to happen. Exciting 4 1/2 months left in 2017. Could see fantastic SP appreciation if a large partnership announced. If not currently invested in IPIX, watch this like a hawk and jump on it as soon as partnership announced. Above is my opinion except for the already announced successful trials for ABSSI (antibiotic) and UP and UPS (Upper colitis and lower colitis).